30-Jan-2025
No headlines found.
Tango Therapeutics to Present at the Guggenheim SMID Cap Biotechnology Conference
Globe Newswire (Thu, 30-Jan 7:00 AM ET)
Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Business Wire (Tue, 3-Dec 7:00 AM ET)
Tango Therapeutics to Present at the Piper Sandler 36th Annual Healthcare Conference
Business Wire (Wed, 27-Nov 7:00 AM ET)
Tango Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Highlights
Business Wire (Wed, 6-Nov 7:05 AM ET)
Business Wire (Wed, 6-Nov 7:00 AM ET)
Tango Therapeutics Inc is a biotechnology company. It is dedicated towards discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. Its program TNG908, is an MTA-cooperative inhibitor of PRMT5 designed to work selectively in cancer cells with an MTAP deletion. Its pipeline further consists of discovery programs such as, TNG462, TNG348, TNG260 and others for multiple cancer types with limited treatment options.
Tango Therapeutics trades on the NASDAQ stock market under the symbol TNGX.
As of January 30, 2025, TNGX stock price was flat at $3.11 with 421,493 million shares trading.
TNGX has a beta of -0.36, meaning it tends to be less sensitive to market movements. TNGX has a correlation of 0.00 to the broad based SPY ETF.
TNGX has a market cap of $334.07 million. This is considered a Small Cap stock.
Last quarter Tango Therapeutics reported $12 million in Revenue and -$.27 earnings per share. This beat revenue expectation by $4 million and exceeded earnings estimates by $.10.
In the last 3 years, TNGX traded as high as $13.03 and as low as $2.47.
The top ETF exchange traded funds that TNGX belongs to (by Net Assets): VTI, IWM, VXF, IWO, SCHA.
TNGX has underperformed the market in the last year with a return of -74.1%, while the SPY ETF gained +24.7%. In the last 3 month period, TNGX fell short of the market, returning -45.5%, while SPY returned +4.7%. However, in the most recent 2 weeks TNGX has outperformed the stock market by returning +11.9%, while SPY returned +2.3%.
TNGX support price is $2.95 and resistance is $3.27 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that TNGX shares will trade within this expected range on the day.